Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Novembro 2023 - 5:15PM
Inozyme Pharma, Inc. (Nasdaq: INZY)(“Company” or “Inozyme”), a
clinical-stage rare disease biopharmaceutical company developing
novel therapeutics for the treatment of pathologic mineralization
and intimal proliferation, today announced that it granted stock
options to new employees to purchase shares of the Company’s common
stock, pursuant to the Company’s 2023 Inducement Stock Incentive
Plan, each as an inducement material to the new employees entering
into employment with the Company in accordance with Nasdaq Listing
Rule 5635(c)(4).
The Company’s compensation committee granted nonstatutory stock
options to purchase up to an aggregate of 116,500 shares of the
Company’s common stock to three new employees on November 1, 2023,
at an exercise price of $2.89 per share, the closing price per
share of the Company’s common stock as reported by Nasdaq on
November 1, 2023. The options have a ten-year term and vest over
four years, with 25% of the original number of shares vesting on
the first anniversary of the applicable employee’s start date and
2.0833% of the shares underlying the option vesting monthly
thereafter, subject to such employee’s continued service to the
Company through the applicable vesting dates.
About Inozyme Pharma
Inozyme Pharma, Inc. is a clinical-stage rare disease
biopharmaceutical company developing novel therapeutics for the
treatment of diseases impacting the vasculature, soft tissue, and
skeleton. Inozyme is developing INZ-701, an enzyme replacement
therapy, to address pathologic mineralization and intimal
proliferation which can drive morbidity and mortality in these
severe diseases. INZ-701 is currently in clinical trials for the
treatment of ENPP1 Deficiency and ABCC6 Deficiency.
For more information, please visit www.inozyme.com or follow
Inozyme on LinkedIn, X
(formerly Twitter), and Facebook.
ContactsInvestors:Inozyme PharmaStefan Riley,
Director of IR and Corporate Communications(857)
330-8871stefan.riley@inozyme.com
Media:SmithSolveMatt Pera(973)
886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Inozyme Pharma (NASDAQ:INZY)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024